The phosphodiesterase inhibitor, enoximone, was previously shown to cause paradoxical effects on cardiac lipid metabolism. The present study was undertaken to elucidate the effects of enoximone on the hepatic mitochondrial pathway of fatty acid oxidation. Results presented here show that in isolated rat liver mitochondria, palmitate oxidation was inhibited progressively by increasing concentrations of enoximone. Maximum inhibition (35%) of mitochondrial oxygen uptake was attained at 250 microM enoximone. At this concentration, enoximone did not affect the oxidation of either palmitoyl-CoA or palmitoyl carnitine. Also, enoximone did not inhibit the oxidation of the short-chain fatty acid, hexanoate, neither did it affect the respiratory chain in the mitochondria. These data suggest that enoximone specifically inhibits long-chain acyl-CoA synthetase activity. This was confirmed experimentally when the activity of this enzyme was determined in the absence and presence of enoximone. Discovering inhibitors of specific steps in lipid metabolism should provide a useful tool to investigate mechanisms regulating this pathway.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/0378-4274(94)90070-1 | DOI Listing |
Clin Trials
December 2024
Institute of General Practice and Public Health, Claudiana-College of Health Professions, Bolzano, Italy.
Background: Enoximone, a phosphodiesterase III inhibitor, was approved in Germany in 1989 and initially proposed for heart failure and perioperative cardiac conditions. The research of Joachim Boldt and his supervisor Gunter Hempelmann came under scrutiny after investigations revealed systematic scientific misconduct leading to numerous retractions. Therefore, early enoximone studies by Boldt and Hempelmann from 1988 to 1991 were reviewed.
View Article and Find Full Text PDFEur Cardiol
November 2024
National Heart and Lung Institute, Faculty of Medicine, Imperial College London London, UK.
Cardiogenic shock (CS) is a critical condition with high mortality rate, as the current management of CS presents significant challenges. Exploration of more effective therapies is necessitated. This review article comprehensively examines the efficacy and safety of levosimendan in the management of CS.
View Article and Find Full Text PDFPharmaceutics
September 2024
Department of Pharmacy, University of Pisa, 56126 Pisa, Italy.
Background: Phosphodiesterase (PDE) inhibitors are gaining interest in the context of pulmonary pathologies. In particular, the PDE3 inhibitor enoximone (ENXM) has shown potential relative to the cure of asthma, chronic obstructive pulmonary disease (COPD), and acute respiratory distress syndrome (ARDS). Despite its administration via inhalation being planned for use against COVID-19 related ARDS (C-ARDS), presently, no inhalable medicine containing ENXM is available.
View Article and Find Full Text PDFInt Immunopharmacol
December 2024
College of Pharmacy, Chung-Ang University, Seoul 06974, Republic of Korea. Electronic address:
Atopic dermatitis (AD) is an inflammatory skin disease that affects approximately 15-20 % of the children and 1-3 % of the adults worldwide. Corticosteroids and calcineurin inhibitors are used in AD therapy; however, they cause various side effects. Current studies focus on novel therapeutic targets such as phosphodiesterases (PDEs) to mitigate AD.
View Article and Find Full Text PDFMed Sci (Paris)
July 2024
Université Paris-Saclay, Inserm UMR-S 1180, Orsay, France.
Cyclic nucleotide phosphodiesterases (PDEs) modulate neurohormonal regulation of cardiac function by degrading cAMP and cGMP. In cardiomyocytes, multiple isoforms of PDEs with different enzymatic properties and subcellular locally regulate cyclic nucleotide levels and associated cellular functions. This organisation is severely disrupted during hypertrophy and heart failure (HF), which may contribute to disease progression.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!